Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs.

[1]  D. Detweiler.  Electrocardiographic monitoring in toxicological studies: principles and interpretations. , 1983, Advances in experimental medicine and biology.

[2]  B. Lucchesi,et al.  Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol. , 1984, The Journal of pharmacology and experimental therapeutics.

[3]  E. Carmeliet.  Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. , 1985, The Journal of pharmacology and experimental therapeutics.

[4]  K. Nademanee,et al.  Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. , 1985, Circulation.

[5]  D. Roden,et al.  Concentration-dependent pharmacologic properties of sotalol. , 1986, The American journal of cardiology.

[6]  R S Reneman,et al.  An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. , 1989, Journal of pharmacological methods.

[7]  S. Nattel,et al.  Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. , 1989, Journal of the American College of Cardiology.

[8]  L. Soyka,et al.  Clinical safety profile of sotalol in patients with arrhythmias. , 1990, The American journal of cardiology.

[9]  Comparability of the Electrophysiologic Responses and Plasma and Myocardial Tissue Concentrations of Sotalol and its d Stereoisomer in the Dog , 1990, Journal of cardiovascular pharmacology.

[10]  J. Dunn,et al.  Ambulatory electrocardiography in dogs , 1991, Veterinary Record.

[11]  J. Davy,et al.  Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. , 1991, The Journal of pharmacology and experimental therapeutics.

[12]  Ulloa Hm,et al.  Arrhythmia prevalence during ambulatory electrocardiographic monitoring of beagles. , 1995, American journal of veterinary research.

[13]  T. Mitsui,et al.  QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. , 1997, Journal of pharmacological and toxicological methods.

[14]  T. Kennedy.  Managing the drug discovery/development interface , 1997 .

[15]  J. Goodwin.  Holter monitoring and cardiac event recording. , 1998, The Veterinary clinics of North America. Small animal practice.

[16]  C. Hoe,et al.  The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  K. Hashimoto,et al.  Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. , 2000, Toxicology and applied pharmacology.

[18]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[19]  N. Wright,et al.  Use of ambulatory electrocardiography for detection of ventricular premature complexes in healthy dogs. , 2001, Journal of the American Veterinary Medical Association.

[20]  K. Hornbuckle,et al.  Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 , 2001 .

[21]  W S Redfern,et al.  Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. , 2001, Cardiovascular research.

[22]  P. Hockings,et al.  Extended acclimatization is required to eliminate stress effects of periodic blood-sampling procedures on vasoactive hormones and blood volume in beagle dogs , 2002, Laboratory animals.

[23]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[24]  Masahiro Tagawa,et al.  Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs. , 2002, Experimental animals.

[25]  G. Bode,et al.  Integration of safety pharmacology endpoints into toxicology studies , 2002, Fundamental & clinical pharmacology.

[26]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[27]  M. Gralinski.  The Dog's Role in the Preclinical Assessment of QT Interval Prolongation , 2003, Toxicologic pathology.

[28]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[29]  Penny Hawkins,et al.  Refinements in telemetry procedures: Seventh report of BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement, Part A , 2003, Laboratory animals.

[30]  M. Schulz,et al.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. , 2003, Die Pharmazie.

[31]  Peter Greaves,et al.  First dose of potential new medicines to humans: how animals help , 2004, Nature Reviews Drug Discovery.

[32]  D. Morton,et al.  Husbandry refinements for rats, mice, dogs and non-human primates used in telemetry procedures , 2004, Laboratory animals.

[33]  Joel Morganroth,et al.  Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug development. , 2004, Journal of electrocardiology.

[34]  P. Waller,et al.  Stephens' detection of new adverse drug reactions , 2004 .

[35]  F. Porciello,et al.  24-Hour Ambulatory Electrocardiography in the Dog , 2004, Veterinary Research Communications.

[36]  J. Schneider,et al.  Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. , 2005, European journal of pharmacology.

[37]  H. Suganami,et al.  QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. , 2005, Journal of pharmacological sciences.

[38]  Russell A. Wilke,et al.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2007, Nature Reviews Drug Discovery.

[39]  Anika Ashok,et al.  ICH Harmonised Tripartite Guideline , 2009 .